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Expression of the transcription factors OCT4, SOX2, KLF4, and cMYC (OSKM) reprograms somatic cells into in-
duced pluripotent stem cells (iPSCs). Reprogramming is a slow and inefficient process, suggesting the presence of
safeguarding mechanisms that counteract cell fate conversion. One such mechanism is senescence. To identify
modulators of reprogramming-induced senescence, we performed a genome-wide shRNA screen in primary human
fibroblasts expressing OSKM. In the screen, we identified novel mediators of OSKM-induced senescence and vali-
dated previously implicated genes such as CDKN1A. We developed an innovative approach that integrates single-
cell RNA sequencing (scRNA-seq) with the shRNA screen to investigate the mechanism of action of the identified
candidates. Our data unveiled regulation of senescence as a novel way by which mechanistic target of rapamycin
(mTOR) influences reprogramming.On one hand,mTOR inhibition blunts the induction of cyclin-dependent kinase
(CDK) inhibitors (CDKIs), including p16INK4a, p21CIP1, and p15INK4b, preventing OSKM-induced senescence. On the
other hand, inhibition of mTOR blunts the senescence-associated secretory phenotype (SASP), which itself favors
reprogramming. These contrasting actions contribute to explain the complex effect that mTOR has on reprogram-
ming. Overall, our study highlights the advantage of combining functional screenswith scRNA-seq to accelerate the
discovery of pathways controlling complex phenotypes.
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Supplemental material is available for this article.
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During normal development, cells gradually acquire
more differentiated fates. Several strategies, referred to
as cellular reprogramming, can reverse the natural direc-
tion of the differentiation process. The reprogramming
of somatic cells to a pluripotent state can be achieved by
either nuclear transfer (Gurdon 1962; Wilmut et al.
1997) or cellular fusion between somatic and embryonic
stem (ES) cells (Tada et al. 2001). In addition, the seminal
work of Yamanaka (Takahashi and Yamanaka 2006)
showed that the expression of pluripotency-associated
factors (OCT4, SOX2, KLF4, and cMYC, collectively re-
ferred to as OSKM) also could be used to reprogram
somatic cells to an ES-like cell type known as induced plu-
ripotent stem cells (iPSCs). This discovery holds great
promise for practical applications in regenerative medi-
cine. Gaining a greater understanding of cellular repro-
gramming will also provide clues about the mechanisms
behind differentiation and dedifferentiation pertinent to
normal development or cancer (Shi et al. 2017).
Reprogramming somatic cells to iPSCs is a long process
with an overall low success rate. The inefficiency of repro-
gramming has suggested the existence of several barriers
impeding iPSC generation. The mechanisms underlying
barriers to cellular reprogramming have been investigated
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previously using functional screens (Qin et al. 2014;
Sakurai et al. 2014; Yang et al. 2014; Cheloufi et al.
2015). An inherent technical difficulty of working with
primary cells is that once in culture, they eventually un-
dergo replicative or stress-induced senescence (Kuilman
et al. 2010). To overcome this issue, genetic tricks to
blunt senescence (for example, overexpressing hTERT or
knocking down p53 expression) have sometimes been
used to screen for genes limiting reprogramming (Qin
et al. 2014), indirectly highlighting that senescence con-
stitutes an intrinsic cellular barrier to iPSC generation
(Krizhanovsky and Lowe 2009; Banito and Gil 2010).
Key tumor suppressors such as p53, p16INK4a, or p21CIP1
control the senescence response to OSKM, and their inhi-
bition increases reprogramming (Banito et al. 2009; Hong
et al. 2009; Kawamura et al. 2009; Li et al. 2009; Marion
et al. 2009; Utikal et al. 2009). However, little else is un-
derstood about the mechanisms governing senescence in-
duction during reprogramming and how similar it is to
other types of senescence.
Senescence is a cellular program that restrains the rep-
lication of damaged or old cells by imposing a stable cell
cycle arrest. As part of the senescence program, cells un-
dergo additional phenotypic alterations, including remod-
eling of their chromatin or secreting a complexmixture of
factors known as the senescence-associated secretory phe-
notype (SASP) (Kuilman et al. 2010; Salama et al. 2014).
Senescent cells are present in injured, preneoplastic, old,
and diseased tissues and influence many phenotypes
through the SASP (Coppe et al. 2010). In general, the accu-
mulation of senescent cells is detrimental (Munoz-Espin
and Serrano 2014), and their elimination ameliorates
many age-related pathologies (Baker et al. 2016), whereas
senescence induction limits fibrosis (Krizhanovsky et al.
2008) and cancer (Collado and Serrano 2010). Senescent
cells found in old or injured tissues also create a permis-
sive environment for in vivo reprogramming (Mosteiro
et al. 2016). This has been linked to increased production
of IL-6 as part of the SASP, as IL-6 facilitates reprogram-
ming by activating cMYC and PIM1 (Brady et al. 2013).
Given the physiological relevance of senescence and
that it constitutes an intrinsic barrier for reprogramming,
understanding how senescence is regulated during repro-
gramming is important. Genetic screening is a powerful
tool that has been exploited with success to identify genes
regulating senescence (Jacobs et al. 2000; Rowland et al.
2005; Acosta et al. 2008; Tordella et al. 2016; Wang et
al. 2016) or cellular reprogramming (Qin et al. 2014;
Sakurai et al. 2014; Yang et al. 2014).
In this study, we screened for shRNAs blunting repro-
gramming-induced senescence. An inherent limitation
of pooled screens is the protracted process of retesting, val-
idation, and characterization of identified candidates. To
speed this up, we combined single-cell RNA sequencing
(scRNA-seq) with shRNA screens. Using this approach,
we discovered that, by regulating senescence,mechanistic
target of rapamycin (mTOR) controls cell-intrinsic and
cell-extrinsic mechanismswith opposing effects on repro-
gramming.Moreover, our study highlights the advantages
of combining functional screenswith scRNA-seq analysis.
Results
Exploring the senescence program induced by OSKM
Expression of the reprogramming factors (OSKM) in
IMR90human fibroblasts causes a senescence-like growth
arrest (Fig. 1A,B) that constitutes an intrinsic barrier to re-
programming (Banito et al. 2009). Similar to oncogenic
RASG12V, the expression of OSKM induces the cyclin-de-
pendent kinase (CDK) inhibitors (CDKIs) p15INK4b,
p16INK4a, and p21CIP1, which are involved in implement-
ing the stable growth arrest associated with senescence
(Fig. 1C).
To better characterize OSKM-induced senescence, we
took advantage of RNA sequencing (RNA-seq). Gene set
enrichment analysis (GSEA) found signatures for senes-
cence and the SASP significantly enriched in the tran-
scriptome of cells expressing OSKM (Fig. 1D). Other
signatures showed a similar association with OSKM-
and RAS-induced senescence. For example, TGF-β-depen-
dent signatures were up-regulated in both types of senes-
cence (Supplemental Fig. S1A). In some instances,
although the effect of RAS or OSKM expression was qual-
itatively equivalent, the strength of the responses differed.
For example, although signatures associated with prolifer-
ation were down-regulated upon RAS or OSKM expres-
sion (Supplemental Fig. S1B), a stronger growth arrest
was associated with RAS expression (Fig. 1E). Overall,
we observed a moderate correlation between the tran-
scriptional changes induced by RAS and OSKM (Spear-
man correlation = 0.33) (Fig. 1F). Among the genes
regulated in common (Fig. 1G; Supplemental Fig. S1C),
gene ontology (GO) analysis highlighted several senes-
cence processes (such as down-regulation of terms related
to mitosis and cell cycle or up-regulation of inflammatory
responses) (Fig. 1H; Supplemental Fig. S1D). Besides these
commonalities, the specific nature of the OSKM and RAS
transcriptional programs was also evident. For example,
GO terms associated with epithelial-to-mesenchymal
transition and development and differentiation processes
were preferentially regulated by OSKM rather than RAS
expression (Fig. 1I; Supplemental Fig. S1E). Overall, the
above results confirm that OSKM expression induces a
senescence program with distinctive characteristics.
A screen for shRNAs regulating OSKM-induced
senescence
To identify genes that regulate OSKM-induced senes-
cence, we screened a shRNA library comprised of
∼58,000 shRNAs (Supplemental Fig. S2A). IMR90 fibro-
blasts were transduced with a retroviral vector expressing
OSKM followed by lentiviral transduction with the
shRNA library. Cells were passaged to enrich for shRNAs
blunting the senescence growth arrest. In parallel, cells
were infected with a shRNA against p53 (shp53), which
prevents the senescence growth arrest (Supplemental
Fig. S2B). Integrated shRNAswere identified, and their en-
richment was assessed using next-generation sequencing
(NGS) (Supplemental Fig. S2C). Five-hundred-fifty-four
Aarts et al.
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candidate genes were selected using the criteria described
in Supplemental Figure S2A. A shRNA library targeting
these candidates (average coverage of six shRNAs per
gene; 3153 shRNAs in total) was generated and screened
similarly (Fig. 2A). Statistical analysis identified shRNAs
significantly enriched with time in OSKM-expressing
cells (day 37 vs. day 0) (Fig. 2B,C). After retesting shRNAs
targeting the top screen candidates, we found that infec-
tion with shRNAs targeting four of these genes
(CDKN1A, MTOR, MYOT, and UBE2E1) resulted in a
consistent bypass of OSKM-induced senescence (Fig. 2D;
Supplemental Fig. S2D).
Figure 1. Expression of OSKM results in the induction of a characteristic senescence program in IMR90 human fibroblasts. (A) Senes-
cencemarkers in IMR90 fibroblasts infectedwith control (vector), a polycistronic vector expressingOSKMor RAS. At 12 d after infection,
senescence was assayed by crystal violet staining (top), senescence-associated β-galactosidase (SA-β-Gal) activity (middle), and BrdU in-
corporation after an 18-h pulse (bottom). Bar, 100 µM. (B) Quantification of BrdU and SA-β-Gal-positive cells after infection with the in-
dicated vectors. (∗∗∗) P < 0.001. (C ) Quantitative RT–PCR (qRT–PCR) showing the mRNA expression levels of CDKN2B (encoding
p15INK4b), CDKN2A (p16INK4a), and CDKN1A (p21CIP1) after infection with the indicated vectors. (∗) P < 0.05; (∗∗∗) P < 0.001. (D) Gene
set enrichment analysis (GSEA) showing enrichment of signatures associated with senescence and the SASP in OSKM versus vector-ex-
pressing IMR90 cells. (NES)Normalized enrichment score. (E) Heatmap showing gene expression of cell cycle genes (Chang et al. 2004) for
IMR90 cells infectedwith vector, RAS, andOSKM. Log2 expression values (rlog) were row-normalized usingZ-scores, and only genes that
have higher expression in RAS or OSKM compared with vector are shown in the heat map. Both genes and samples were clustered using
hierarchical clustering. (F ) Scatter plot showing log2 fold change (FC) in gene expression between RAS versus vector and OSKM versus
vector. Genes changing (false discovery rate [FDR] < 0.05; log2 fold change <−1 or log2 fold change > 1) are shown in color. (G) Venn dia-
gram showing common down-regulated genes between RAS versus vector and OSKM versus vector. Down-regulated genes were defined
as those with log2 fold change <−1 and FDR < 0.05. (H,I ) Gene ontology (GO) term analysis of common genes down-regulated upon
OSKM- and RAS-induced senescence (H) or down-regulated only in OSKM-induced senescence (I ). First, for each senescence type, genes
differentially regulated comparedwith control (vector) by log2 fold change <−1 (P < 0.05) were selected.Next, common geneswere upload-
ed to the online bioinformatics database Metascape (http://metascape.org) for GO term detection and clustering. Same-colored dots fall
into a function category similar to the given title. Only statistically significant categories (P < 0.05) are shown.
Single-cell RNA profiling of shRNA screens
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Figure 2. An shRNA screen identifies modulators of reprogramming-induced senescence. (A) Time line and strategy of a secondary
shRNA enrichment screen. IMR90 fibroblasts were infected with an OSKM expression vector followed by a pooled shRNA library in
duplicate. Samples for analysis of shRNA library representation were taken at regular intervals over a 37-d culture period. Two indepen-
dent biological shRNA screens were performed. (B) Volcano plot depicting the changes in representation (log2 fold change; X-axis) and
significance (−log10-converted P-value; Y-axis) of each shRNA in the library at day 37 versus day 0. Total library (black; 3153 shRNAs),
enriched shRNAs (gray; P < 0.05; FDR < 0.25; 229 shRNAs), and candidates withmultiple shRNAs (blue; log2 fold change > 1; 52 shRNAs)
are shown. The top shRNAs targeting CDKN1A and MTOR are highlighted. EdgeR statistical analysis was used to combine and batch-
correct data from two independent biological screens. (C ) Significantly enriched (log2 fold change) shRNAs for CDKN1A,MTOR,MYOT,
andUBE2E1. (D) Initial validation of candidates identified in the secondary screen. IMR90 fibroblasts were infectedwith control or OSKM
expression vector and pooled pGIPZ shRNAs against the indicated candidates. Cell proliferationwas assayed by crystal violet staining. (E)
IMR90 fibroblasts were infected with OSKM followed by two different shRNAs against p21, MTOR, MYOT, and UBE2E1. At 12 d after
infection, cells were seeded at low density. After 16 d, plateswere stainedwith crystal violet. Images are froma representative experiment.
(F ) IMR90 fibroblasts were infectedwith empty vector (gray bars) or OSKM (black bars) followed by shp53 or two different shRNAs against
p21,MTOR,MYOT, andUBE2E1 or control vector (V). At 12 d after infection, cells were seeded in 96-well plates and cultured for another
5 d. The percentage of BrdU-positive cells was determined by immunofluorescence after an 18-h pulsewith BrdU. Error bars represent the
SD of three independent experiments. (∗) P < 0.05; (∗∗) P < 0.01; (ns) not significant. (G) IMR90 fibroblasts were treated as described in F. At
12 d after infection, cells were seeded in 96-well plates. The next day, SA-β-Gal activity was determined by fluorescence staining. Repre-
sentative images are shown for cells infected with the indicated vectors. Bar, 30 µm. (H) Quantification of SA-β-Gal-positive cells treated
as described in G. (Gray bars) Cells infected with empty vector control (V); (black bars) cells infected with OSKM vector. Error bars rep-
resent the SD of at least three independent experiments. (∗) P < 0.05; (∗∗) P < 0.01; (∗∗∗) P < 0.001; (ns) not significant.
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To validate the screen results, IMR90 fibroblasts were
infected with OSKM and two individual shRNAs target-
ing each candidate. We assessed the ability of the different
shRNAs to knock down their targets (Supplemental Fig.
S3A–C).MYOT expression was below the detection limit,
and its knockdown could not be confirmed despite inde-
pendent shRNAs reproducing the bypass of senescence
phenotype (data not shown). The ability of shRNAs tar-
geting CDKN1A,MYOT,MTOR, andUBE2E1 to prevent
OSKM-induced senescence was confirmed by increased
proliferation (Fig. 2E), a higher percentage of cells in-
corporating BrdU (Fig. 2F; Supplemental Fig. S3D), and a
decrease in the percentage of senescence-associated β-
galactosidase (SA-β-Gal)-positive cells when compared
with IMR90 cells infected with OSKM and a control
vector (Fig. 2G,H; Supplemental Fig. S3E). Since p21CIP1
has been implicated previously in controlling repro-
gramming-induced senescence (Banito et al. 2009), these
results suggest that our screen successfully identified
genes regulating senescence.
scRNA-seq as an approach to facilitate the analysis
of shRNA screens
An important bottleneck in genetic screens such as the
one described in this study is the retesting, validation,
and characterization of the identified candidates. The ad-
vent of scRNA-seq has made it possible to analyze gene
expression at a cellular level rather than relying on aver-
age levels from cell populations (Tanay and Regev 2017).
We hypothesized that by performing scRNA-seq in paral-
lel with measuring shRNA enrichment in bulk popu-
lations, the characterization of our screen candidates
could be accelerated.
Toevaluate this approach,we first assessed the accuracy
of detecting shRNAs in single cells (Fig. 3A). The shRNAs
were embedded in miR-E, an improved miR-30-based
backbone (Fellmann et al. 2013), which is expressed from
a RNA polymerase II (Pol II)-dependent promoter (Dickins
et al. 2005). While most shRNA transcripts use the polya-
denylation (poly-A) signal in the 3′ long terminal repeat
(LTR) of the virus, we noted the presence of two putative
poly-A signals (ATTAAA) in the 3′ context of miR-E, rais-
ing thepossibility thatprotocols relyingonpoly-Apriming
could detect those transcripts. To call the shRNAs, we
used reads that mapped to the shRNA-specific sequence
and overlapped with the miR-E backbone (Supplemental
Fig. S4A). The shRNA reads correlatedwith the total num-
ber of reads per cell (Supplemental Fig. S4B) and were de-
tected only in cells transduced with shRNAs (Fig. 3B).
Most cells contained a single shRNA (116 out of 300 cells)
(Fig. 3C), and most shRNAs were present in just one cell
(310 out of 359 shRNAs) (Fig. 3D).
Next, we performed scRNA-seq of IMR90 cells infected
with OSKM and specific shRNAs (as summarized in Fig.
3E). Cells were infected independently with different
shRNAs targeting each screen candidate (three shRNAs
targetingMTOR and CDKN1A and two targeting MYOT
and UBE2E1, respectively). The scRNA-seq information
allowed us to assign shRNAs to most of the cells (Fig.
3E), and transcriptome analysis confirmed the down-regu-
lation of TP53, CDKN1A, MTOR, and UBE2E1 in cells
infected with the corresponding shRNAs (Fig. 3F). More-
over, CDKN1A, a p53 target gene, was also down-regulat-
ed in OSKM–shp53 cells. We could not detect MYOT
expression, as in our previous experiments.
Finally, to understand whether the scRNA-seq data
could identify expression differences associated with the
knockdown of the different candidates, we performed un-
supervised hierarchical clustering (Fig. 3G; Supplemental
Fig. S4C). The cells segregated into five stable clusters,
each enriched for cells infected with shRNAs targeting a
different gene. We used t-distributed stochastic neighbor
embedding (t-SNE) analysis to further characterize the
different subclusters and observed that the biggest deter-
minant was the difference betweenOSKM-induced senes-
cent versus growing (vector) cells (Fig. 3H). Nonetheless,
differences associated with the knockdown of the screen
candidates were detected, as exemplified by the projec-
tion of selected marker genes identified by clustering
(Supplemental Fig. S4D).
Coupling scRNA-seq to the shRNA screen identifies
profiles associated withMTOR knockdown
Taking advantage of the approach described above, we
sorted 288 cells from the screen to carry out scRNA-seq.
In parallel, we isolated genomic DNA for identification
of shRNAs by NGS (Fig. 4A). At an arbitrary cutoff of
>10 shRNA reads, we identified shRNAs in 211 out of
288 cells. Among those, we identified 122 out of 211 cells
with shRNAs targeting MTOR and 12 out of 211 cells
with shRNAs targeting CDKN1A, two of the screen hits
(Fig. 4B). As expected,MTOR expression was significantly
down-regulated in cells expressing the MTOR shRNA
(Supplemental Fig. S5A). Next, we clustered the scRNA-
seq data derived from the screen (Fig. 4C). The transcrip-
tomes stably segregated into four clusters that were com-
prised mainly of vector cells, OSKM cells, OSKM–
shMTORcells, and cells with shRNAs thatwere not iden-
tified as enriched in the screen (other shRNAs) (Fig. 4C;
Supplemental Fig. S5B). Using t-SNE, we visualized cell
separation (Fig. 4D) and the expression of genes differen-
tially expressed in distinct cell populations (Supplemental
Fig. S5C).
The scRNA-seq data helped us understand how mTOR
regulates OSKM-induced senescence and place it in
the context of reprogramming. Cells with reduced
MTOR expression showed reduced levels of different
CDKIs (such as CDKN2A, CDKN1A, and, most notably,
CDKN2B) (Fig. 4E). In addition, cells bearing shRNAs
targeting MTOR down-regulated multiple SASP compo-
nents, including IL6, IL8, and INHBA (Fig. 4E; data not
shown). Moreover, GSEA showed that signatures related
to senescence, SASP, and TGF-β, among others, were sig-
nificantly down-regulated in OSKM–shMTOR cells
(Fig. 4F; Supplemental Fig. S5D). Therefore, scRNA-seq
served to identify candidate genes and pathways that
could explain how MTOR regulates OSKM-induced
senescence.
Single-cell RNA profiling of shRNA screens
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Figure 3. Coupling scRNA-seq with shRNA assignment identifies expression profiles associated with gene knockdown. (A) Strategy of
scRNA-seq analysis of IMR90 cells infectedwith OSKM and an shRNA library. RNA-seq libraries were prepared using the ICELL8 single-
cell system. (B) The number of shRNA-specific reads plotted for IMR90 cells infected with empty shRNA vector (no shRNA-specific in-
sert; n = 50), OSKM and shRNA library cells (OSKM/Lib; n = 300), and K562 control cells that were not exposed to shRNAvectors (n = 50).
(C ) Pie chart showing the number of different shRNAs that could be detected per cell. One or more shRNAs could be detected in 82% of
the single-cell libraries (246 out of 300), while 18% (54 out of 300) had no detectable shRNA reads. (D) Pie chart showing the occurrence of
the 359 different shRNAs thatwere detected in 300OSKM/LibRNA-seq libraries. Overall, 86% (310 out of 359) of the shRNAswere found
uniquely in one cell, while 14% (49 out of 359) of the hairpinswere detected in two ormore cells. (E) Experimental setup of the scRNA-seq
experiment. Vector or OSKM-expressing IMR90 cells were infected with the indicated shRNAs. For each condition, 40 single cells were
used for scRNA-seq analysis. RNA-seq librarieswere prepared using the ICELL8 single-cell system (WaferGenBiosystems). (F ) Violin plots
of TP53,CDKN1A,MTOR, andUBE2E1mRNA expression of single cells infected with the indicated constructs. (G) Heat map and clus-
tering analysis of differentially expressed genes ofOSKM-expressing cells infectedwith vector, shp21, shMTOR, shMYOT, and shUBE2E1
resulted in five clusters, each enriched for cells containing shRNAs targeting a different gene. (H) The t-distributed stochastic neighbor
embedding (t-SNE) plot of the 280 single cells depicts the separation into shp53, shMTOR, shCDKN1A, shMYOT, and shUBE2E1 relative
to vector and OSKM control cells.
Aarts et al.
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TGF-β-mediated p21CIP1 induction contributes toOSKM-
induced senescence
To investigate howMTOR regulates senescence, we com-
pared the effect of knocking down MTOR in OSKM- or
RAS-induced senescence. While MTOR depletion pre-
vented OSKM-induced senescence, it did not affect the
RAS-induced senescent arrest (Fig. 5A). This was consis-
tent with our previous data (Herranz et al. 2015). Indeed,
treatment with themTOR inhibitor rapamycin prevented
the arrest caused by OSKM but not that induced by RAS
expression (Fig. 5B). Transcriptome analysis confirmed
Figure 4. Integrating scRNA-seq analysis with an shRNA screen. (A) Time line and strategy of a secondary shRNA enrichment screen
combined with scRNA-seq. IMR90 fibroblasts were infected as described in Figure 2A. From the second repeat screen, 288 single cells
were sorted fromone replicate at day 56 for transcriptome analysis byRNA-seq in parallel with genomicDNA isolation for shRNAenrich-
ment analysis. scRNA-seq libraries were prepared using the Smart-seq2 protocol (Picelli et al. 2014). (B) Pie chart representing the shRNA
occurrence among 288 single-cell libraries. The shRNAread count thresholdwas set at≥10 for identification of shRNAs. (C ) Heatmap and
clustering analysis of differentially expressed genes of OSKM/Lib cells compared with vector and OSKM cells results in separation of
OSKM-expressing cells containing an shRNA againstMTOR versus other shRNAs. (D) The t-SNE plot of the 288 single OSKM/Lib cells
depicts the separation into shMTOR, shCDKN1A, and other shRNAs relative to vector and OSKM control cells. (E) Projection ofMTOR,
IL6, IL8, CDKN1A, CDKN2A, and CDKN2B onto the t-SNE plot from D is shown. (F ) GSEA showing loss of signatures associated with
senescence, the SASP, and TGF-β in OSKM–shMTOR cells versus OSKM control cells. (NES) Normalized enrichment score.
Single-cell RNA profiling of shRNA screens
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that rapamycin restored expression of proliferation-asso-
ciated genes in OSKM-expressing but not RAS-expressing
cells (Supplemental Fig. S6A). Based on the scRNA-seq
data, we examined the expression ofCDKN2A,CDKN2B,
and CDKN1A to understand how mTOR inhibition
prevents OSKM-induced (but not RAS-induced) senes-
cence. Consistent with the scRNA-seq data, CDKN2B
was highly induced by OSKM, and this induction was di-
minished upon mTOR inhibition (Fig. 5C). A similar pat-
tern was observed for CDKN2A and CDKN1A, although
the induction was more modest. RAS expression induced
the expression of all threeCDKIsmore robustly. Although
Figure 5. Investigating how mTOR inhibition affects OSKM-induced senescence. (A) Knockdown of MTOR by two different shRNAs
prevented the growth arrest induced by OSKM (top row), but not by RAS (bottom row), as measured by crystal violet staining. (B) Inhibi-
tion of mTOR by rapamycin prevents the growth arrest induced by OSKM (top row) but not by RAS (bottom row). IMR90 fibroblasts were
infected with OSKM or RAS and treated with 0.3 and 1.0 nM rapamycin (Rapa) the next day. At 12 d after infection, cells were seeded at
low density and cultured for 16 more days in the absence of rapamycin before plates were stained with crystal violet. (C,D) Inhibition of
mTOR by rapamycin blunts the induction of CDKIs, but the levels revert back to basal only in OSKM-induced senescence. IMR90 fibro-
blasts were infected with empty vector or OSKM- or RAS-expressing vectors and were treated the next day with DMSO (−) or increasing
doses of rapamycin. At day 10 after infection, the cells were collected for qRT–PCR analysis of mRNA expression (C ) or immunofluores-
cence (D) of the indicated CDKIs. Error bars represent the SD of three independent experiments. (∗) P < 0.05; (∗∗) P < 0.01; (∗∗∗) P < 0.001; (ns)
not significant. Bar, 100 μm. (E)CDKN2B,CDKN2A, andCDKN1A are up-regulated byOSKMexpression, but only the latter two are nec-
essary for OSKM-induced growth arrest. IMR90 fibroblasts were infected with empty vector or OSKM-expressing vector and, 2 d later,
transfectedwith scramble siRNA (−), the indicated siRNAs, or combinations of siRNAs. BrdU quantificationwas performed at day 7 after
infection. Error bars represent the SD of three independent experiments. (∗) P < 0.05; (∗∗) P < 0.01; (∗∗∗) P < 0.001; (ns) not significant. (F )
GSEA showing loss of a TGF-β signature in OSKMcells treatedwith 10 nM rapamycin versus OSKMcells. (NES) Normalized enrichment
score. (G) Signaling via TGF-β RI kinase is necessary for the induction of the three CDKIs in OSKM-induced senescence but not RAS-in-
duced senescence. IMR90 fibroblasts were infected with empty vector or OSKM- or RAS-expressing vectors and treated the next day with
DMSO (−) or 23 nMTGF-β RI kinase inhibitor II (A; Calbiochem, 616452). At day 10 after infection, the cells were collected for qRT–PCR
analysis of mRNA expression of the indicated CDKIs. Error bars represent the SD of three independent experiments. (∗) P < 0.05; (ns) not
significant. (H) Signaling via TGF-β RI kinase is necessary for OSKM-induced growth arrest but not RAS-induced growth arrest. IMR90
fibroblasts were infected with empty vector or OSKM- or RAS-expressing vectors and treated with DMSO (−) or 23 nM TGF-β RI kinase
inhibitor II (A; Calbiochem, 616452). BrdU quantification was performed at day 9 after infection. Error bars represent the SD of three in-
dependent experiments (∗∗) P < 0.01; (ns) not significant.
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treatmentwith rapamycin blunted the up-regulation of all
three CDKIs in response to either OSKM or RAS expres-
sion, their expression only came back to (or below) basal
levels in OSKM-expressing cells treated with rapamycin
(Fig. 5C). Analysis of p16INK4a expression by Western
blot or immunofluorescence analysis confirmed both a
lower induction of p16INK4a levels and a stronger decrease
upon rapamycin treatment in OSKM-expressing cells
than in RAS-expressing cells (Fig. 5D; Supplemental Fig.
S6B).
We next examined the relative contribution of
CDKN1A, CDKN2A, and CDKN2B to OSKM-induced
senescence. Despite the extent of CDKN2B induction
(Figs. 4E, 5C), CDKN2B knockdown with two indepen-
dent siRNAs did not prevent the growth arrest caused
by OSKM (Fig. 5E; Supplemental Fig. S6C; data not
shown). On the other hand, knocking down CDKN1A or
CDKN2A blunted the OSKM-induced arrest, but again,
no additional effect was observed upon CDKN2B knock-
down (Fig. 5E; Supplemental Fig. S6D,E).
To further understand the mechanism behind the
MTOR-dependent induction of senescence by OSKM, we
searched for pathways that could explain the induction of
CDKIs. In this regard, the scRNA-seq data and the fol-
low-up analysis highlighted that TGF-β signaling was in-
duced by OSKM (Supplemental Fig. S1A) and affected by
shMTOR (Fig. 4F) or rapamycin treatment (Fig. 5F). Both
CDKN1A and CDKN2B are well-known effectors of the
TGF-β pathway (Reynisdottir et al. 1995), and p16INK4a
can be induced by TGF-β during senescence (Vijayachan-
dra et al. 2009). Interestingly, TGFBRI inhibition pre-
vented the up-regulation of CDKN2B, CDKN1A, and
CDKN2A by OSKM expression but had just minimal im-
pact in response to RAS expression (Fig. 5G).Moreover, in-
hibition of TGFBRI signaling blunted the growth arrest
triggered by OSKM (Fig. 5H). The above results suggest
that increased TGF-β signaling is important to induce
p21CIP1 and other CDKIs in response to OSKM induction
and that mTOR inhibition interferes with this pathway
to prevent senescence.
Regulation of senescence by mTOR has opposing cell-
intrinsic and cell-extrinsic effects on reprogramming
Senescence imposes a cell-intrinsic barrier to reprogram-
ming (Banito et al. 2009). To investigate how the identi-
fied regulators of OSKM-induced senescence affect iPSC
generation, we performed reprogramming of mouse em-
bryonic fibroblasts (MEFs) with constitutive Cas9 ex-
pression and a Nanog-GFP reporter using a piggyBac
transposon carrying doxycycline (dox)-inducible MKOS-
ires-mOrange and a U6-driven guide RNA (gRNA) expres-
sion cassette. The effectiveness of the gRNA sequences
was confirmed by infecting Cas9-expressing MEFs with
lentiviral gRNA expression vectors (Supplemental Fig.
S7A; Tzelepis et al. 2016). As controls, we used gRNAs
targeting Pecam (not affecting reprogramming), Stat3
(negative effect), and Rb1 (positive effect). In line with
previous evidence, knocking out p21CIP1 increased the
numbers of both total and Nanog-positive colonies (Fig.
6A; Supplemental Fig. S7B,C). Unexpectedly knocking
Myot or Ube2e1 out did not affect reprogramming (Sup-
plemental Fig. S7B,C). On the contrary, Mtor knockout
had a negative impact on reprogramming (Fig. 6A; Supple-
mental Fig. S7B,C). Although there may be many other
possible explanations, these results suggest that prevent-
ing senescence per se does not necessarily result in an
increase in reprogramming.
It had been shown previously that mTOR exerts a dose-
and time-dependent effect on reprogramming (Chen et al.
2011), which might explain the detrimental effect ob-
served upon its knockout. To further dissect the role of
Mtor in reprogramming and understand the contribution
of senescence regulation, we took advantage of the
mTOR inhibitor rapamycin. Short treatment with nano-
molar doses of rapamycin enhanced reprogramming,
while more sustained treatment decreased reprogram-
ming (Fig. 6B,C).
Regulation of reprogramming by mTOR has been con-
nected to its ability to control autophagy (Wang et al.
2013; Wu et al. 2015), but, so far, no link has been estab-
lished with the ability of mTOR to regulate senescence.
Since we showed that mTOR regulates senescence via
TGF-β-dependent regulation of p21CIP1 and other CDKIs,
we examined how interfering with this pathway affected
reprogramming.While a TGF-β inhibitor (Alk5i) or the de-
scribed short-term rapamycin increased reprogramming
efficiency, no further increase was observed by the com-
bined treatment (Fig. 6D), which suggests an overlap in
the action of both inhibitors. To more directly examine
the relation between mTOR inhibition, senescence, and
reprogramming, we knocked out p21CIP1. As shown previ-
ously, p21CIP1 knockout significantly increased repro-
gramming. Importantly, rapamycin treatment did not
result in any additional increase, suggesting again that
mTOR inhibition contributes to increase reprogramming
efficiency by blunting senescence (Fig. 6D).
Together with previous findings, our results suggest a
dual role for mTOR during reprogramming. While senes-
cence is detrimental for reprogramming (Banito et al.
2009), the SASP favors reprogramming (Mosteiro et al.
2016), suggesting the coexistence of contrasting cell-in-
trinsic and cell-extrinsic effects. The scRNA-seq data
showed thatMTOR knockdown reduces SASP induction
in response to OSKM expression (Fig. 4E,F). Previous
work has shown that specific SASP components such
as IL-6 can promote reprogramming (Mosteiro et al.
2016). The scRNA-seq showed that IL-6 was among sev-
eral SASP components whose induction was reduced by
mTOR inhibition (Fig. 4E), which we confirmed by quan-
titative RT–PCR (qRT–PCR) (Supplemental Fig. S7D). To
understand whether mTOR inhibition could affect repro-
gramming by altering the SASP, we cultured TNG
MKOS MEFs in the presence of different conditioned
media (CMs). CM of senescent MEFs, but not that of
MEFs in which Mtor expression was down-regulated, en-
hanced reprogramming efficiency (Fig. 6E; Supplemental
Fig. S7E). Moreover, coculture of TNG MKOS MEFs
with either control or senescent MEFs (expressing
RASG12V) or senescent MEFs infected with shMtor
Single-cell RNA profiling of shRNA screens
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constructs rendered similar results (Supplemental Fig.
S7F). Overall, the above experiments suggest that regula-
tion of senescence by mTOR exerts opposing effects dur-
ing cellular reprogramming (as summarized in Fig. 6F).
Discussion
A better understanding of the mechanisms regulating cel-
lular reprogramming is needed to increase its efficiency.
Multiple efforts have been made to identify the different
barriers that inherently limit cellular reprogramming
(Qin et al. 2014; Sakurai et al. 2014; Yang et al. 2014). Sen-
escence is one of these cell-intrinsic barriers (Banito et al.
2009). Despite the pathophysiological relevance of senes-
cence, not much is known about how senescence is regu-
lated during reprogramming beyond the involvement of
the key tumor suppressors p53, p16INK4a, and p21CIP1
(Krizhanovsky and Lowe 2009; Banito and Gil 2010).
To gain further insight, we screened for shRNAs pre-
venting OSKM-induced senescence. Our assay identified
genes regulating OSKM-induced senescence without
the confounding effects of reprogramming itself. We iden-
tified shRNAs targeting four genes: CDKN1A, MTOR,
MYOT, and UBE2E1. While CDKN1A (which encodes
for p21CIP1) andMTOR had been shown previously to reg-
ulate senescence or senescence-related phenotypes, this is
the first evidence suggesting thatMYOT andUBE2E1 reg-
ulate senescence. MYOT encodes for myotilin, whose
main known function is to be part of the Z-disc of sarco-
meres (Otey et al. 2005). Despite identifying multiple
shRNAs targeting MYOT in the screen and confirming
their effects with two independent shRNAs, expression
of MYOT was hard to detect in IMR90 cells. UBE2E1 is
Figure 6. Dual effect of mTOR inhibition
in iPSC reprogramming. (A) Reprogramming
of Cas9-expressing TNG MKOS MEFs was
initiated 1 d after transfection with a piggy-
Bac transposon carrying an inducibleMKOS
cassette and the indicated gRNA expression
gRNAexpression cassette. Numbers of total
and Nanog-GFP+ colonies were counted on
day 14. See Supplemental Figure S7, B and
C, for an expanded version of this figure. Er-
ror bars represent the SD of three indepen-
dent experiments. (∗) P < 0.05; (∗∗) P < 0.01;
(∗∗∗) P < 0.001; (ns) not significant. (B) Dose-
and time-dependent effect of rapamycin on
reprogramming. Rapamycin (0.3 and 1.0
nM) was added for 3, 6, or 14 d after MKOS
induction. Resulting iPSC colonies were
stained for alkaline phosphatase (AP) after
14 d. Data were normalized to untreated
cells. Error bars represent the SD of three in-
dependent experiments (days 0–3 and 0–6).
Data from one experiment are shown for
days 0–14. (∗) P < 0.05; (∗∗) P < 0.01; (∗∗∗) P <
0.001. (C ) Dose-dependent effect of rapamy-
cin on reprogramming. Rapamycin (0.3 and
1.0 nM)was added for 3 d afterMKOS induc-
tion. Resulting iPSC colonies were stained
for alkaline phosphatase after 14 d. (D) Re-
programming of Cas9-expressing Nanog-
GFP MEFs was performed after transfection
of a piggyBac transposon carrying inducible
MKOS-ires-mOrange and U6-driven gRNA
expression cassettes in the presence or ab-
sence of 500 nM TGF-β RI inhibitor (Alk5i;
Tocris, A83-01) and 5 nM rapamycin (Rap).
Numbers of total and Nanog-GFP+ colonies
were counted on day 14. Error bars represent
the SD of three independent experiments. (∗)
P < 0.05; (∗∗) P < 0.01; (ns) not significant. (Green) Statistics for Nanog+ colonies; (black) statistics for total number of colonies. (E) Repro-
gramming efficiency of transgenic MKOSMEFs treated with conditionedmedium (CM) fromMEFs infected with control vector, RAS, or
RAS and shRNAs againstMtor. CMwas collected after 3 d and reconstituted with 4× concentrated reprogramming medium before being
added to the transgenicMEFs. Alkaline phosphatase-positive (AP+) colonies were counted, and data were normalized to cells treated with
CM from RAS/ctr. Error bars represent the SD of four independent experiments. (∗∗) P < 0.01; (∗∗∗) P < 0.001. Representative images are
shown. (F ) Scheme summarizing the dual action of MTOR on regulation of senescence and reprogramming of iPSCs. (Green arrows) in-
duction; (red arrow) inhibition.
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an E2 ubiquitin-conjugating enzyme (Nuber et al. 1996).
Proteasome-dependent protein degradation had been ob-
served previously during senescence (Deschenes-Simard
et al. 2013). Whether UBE2E1 plays a role in that process
will need to be studied. Given that the role of p21CIP1 in
reprogramming and reprogramming-induced senescence
is well known (Banito et al. 2009; Hong et al. 2009; Kawa-
mura et al. 2009;Marion et al. 2009; Utikal et al. 2009), we
decided to investigate the connection between mTOR,
regulation of senescence, and reprogramming.
In addition, this screen provided us with a platform to
test a new strategy to speed up candidate characterization
by carrying out scRNA-seq in parallel with shRNA en-
richment (Fig. 4A). First, we assessed the feasibility of de-
tecting and assigning shRNAs to single cells. As we used a
miR-30-based shRNA library (Fellmann et al. 2013), we
were able to detect shRNA-specific sequence reads that
could be distinguished from the endogenous mRNA se-
quence by filtering for reads that contained the unique
shRNA hairpin sequence and part of the surrounding
miR-30-based scaffold. We also proved that the detected
shRNAs could be matched with their corresponding tran-
scriptomes. Applying this methodology to our screen, we
detected cells carrying shRNAs against two of the screen
candidates (MTOR and CDKN1A). Due to the size of the
library screened and the number of cells analyzed, we ob-
tained only enough cells to infer information on MTOR.
This limitation could be overcome by increasing the num-
ber of cells analyzed and/or decreasing the size of the li-
brary used for the screen. Recently, Perturb-seq and
CRISP-seq, approaches that linkCRISPR-based functional
screens with scRNA-seq analysis, have been described
(Adamson et al. 2016; Dixit et al. 2016; Jaitin et al.
2016). Although conceptually similar, the CRISPR-based
approaches require the generation of specific vectors, in-
cluding tags to monitor the expression of the single-guide
RNAs (sgRNAs). As the cost of single-cell sequencing de-
creases, the approach described here could easily be scaled
up, increasing the relevance of the information obtained.
Our approach complements CRISPR-based technologies.
For example, the knockdown achieved by shRNAs mim-
ics the partial inhibition caused by drugs better than a
CRISPR-mediated knockout. In addition, our approach
could be used to analyze screens of microRNA (miRNA)
libraries. Since it is believed thatmiRNAs can target mul-
tiple molecules in the same biological pathway, carrying
out GO analysis of scRNA-seq in miRNA screens could
be informative.
Our scRNA-seq analysis served to gain insights into the
regulation ofOSKM-induced senescence bymTORand its
impact on reprogramming. From the scRNA-seq, we ob-
tained information on both genes and pathways affected
by mTOR that served to investigate its mechanism of ac-
tion. Twoof the problems inherent to scRNA-seq are tran-
script detection and dropout rates per cell, which make it
difficult to obtain significant results for individual lowly
abundant genes. By extending our analysis to gene signa-
tures instead, we increased the sensitivity of cell annota-
tion, as the stochastic dropout is unlikely to affect all
genes within a pathway at the same time, as shown previ-
ously (Mackenzie et al. 2017). Using this pathway-centric
approach, we identified signatures affected by shMTOR
from scRNA-seq, which allowed us to describe a role for
TGF-β in regulating the expression of p21CIP1 and other
CDKIs during OSKM-induced senescence.
Several reports have suggested that mTOR inhibition
can enhance reprogramming (Chen et al. 2011; Wang
et al. 2013). The effect is complex; low doses of mTOR
inhibitors or short treatments increase the efficiency of
reprogramming more than higher dosages or longer treat-
ments (Chen et al. 2011). Until now, the experimental ev-
idence focused only on autophagy to explain how mTOR
regulates pluripotency and reprogramming (Wang et al.
2013; Wu et al. 2015). Our screen adds control of senes-
cence as an additional mechanism. During oncogene-in-
duced senescence (OIS), mTOR inhibition blunts SASP
induction without preventing the senescent growth ar-
rest (Herranz et al. 2015). In contrast, inhibiting mTOR
during OSKM-induced senescence prevents both SASP
induction and the senescent growth arrest. Since inhibit-
ing the SASP decreased reprogramming efficiency, our
study suggests an explanation for the dual antagonistic
effects exerted by mTOR during reprogramming. The
SASP comprises many factors, and while some of those
factors favor reprogramming (e.g., IL6 or BMP family
members), others can hinder it (such as TGFβ family
members). Further dissecting which SASP components
play positive or negative roles in reprogramming would
be worth investigating.
Here, we identified mTOR as an important regulator of
senescence during reprogramming. The net effect is ex-
plained in part by the contrasting effects exerted by
mTORover the senescence growth arrest and SASP induc-
tion. Besides clarifying the mechanism by which mTOR
controls reprogramming-induced senescence, our work
showcases the advantages of integrating scRNA-seq to ac-
celerate the identification and characterization of candi-
date genes in functional screens.
Materials and methods
Cell culture
IMR90 human fetal lung fibroblasts (AmericanTypeCulture Col-
lection) were cultured in high-glucose Dulbecco’s modified Eagle
medium (DMEM) (Gibco, 41965) supplemented with 10% fetal
bovine serum (FBS) (Sigma) and 1× antibiotic–anti-mycotic
(Gibco, 15240) and grown at 37°C and 5% CO2. TNG MKOS
MEFs containing a dox-inducible MKOS-IRES-mOrange trans-
gene and a Nanog-GFP reporter were isolated from embryonic
day 12.5 (E12.5) chimeric embryos with a 129 genetic background
as described before (O’Malley et al. 2013). Wild-type MEFs were
prepared from 13.5-d-old embryos of CD-1 mice (Tordella et al.
2016). MEFs were maintained in MEF medium (Glasgow mini-
mum essential medium [GMEM]; Sigma, G5154) supplemented
with 10% EmbryoMax ES cell qualified FBS (Millipore, ES-009-
B), 2 mML-glutamine (Gibco, 25030), 1×MEMnonessential ami-
no acids (NEAA) (Gibco, 11140), 1 mM sodium pyruvate (Gibco,
11360), 1× antibiotic–anti-mycotic (Gibco, 15240), 50 µM 2-mer-
captoethanol (Gibco, 31350) supplementedwith 1 ng/mL heparin
(Sigma, H3149), and 5 ng/mL recombinant human FGF-basic (AA
1-155; Gibco, PHG0264).
Single-cell RNA profiling of shRNA screens
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Plasmids
For de novo generation of miRE-based shRNAs, 97-mer oligonu-
cleotides containing the shRNA fragment were PCR-amplified
using primers miRE-Xho-fw and miRE-EcoOligo-rev and cloned
into the pRLL lentiviral backbone as before (Fellmann et al.
2013). shRNA sequences are listed in Supplemental Table S1.
shRNA libraries and screening
Details of the shRNA libraries used and the screen protocol are in
the Supplemental Material.
Library preparation for determining shRNA enrichment
Genomic DNAwas extracted from 106 cells collected at different
time points during the screen using the Gentra Puregene cell kit
(Qiagen) as described by the manufacturer. Solexa adapters and a
sample-specific barcode (3 nucleotides [nt] for pGIPZ and 4 nt for
pRLL), to allow for multiplexing, were ligated by PCR using 2 μg
of extracted DNA as a template. Individual barcoded PCR prod-
ucts were purified using theQIAquick gel extraction kit (Qiagen),
quantified using the Qubit 2.0 Fluorometer, and pooled by com-
bining equal quantities (40 ng each). Prior to sequencing, the re-
sulting Solexa library was quantified using qPCR and the
Bioanalyzer Agilent high-sensitivity DNAkit (Agilent Technolo-
gies) to estimate the average size of the library. Of the library, 12
pMwas applied to an Illumina flow cell for cluster generation and
sequenced on an Illumina Genome Analyzer IIx system or HiSeq
2500 in rapid-run mode (50-base-pair single read), following the
manufacturers’ protocols.
Statistical analysis of the shRNA screens
FASTA files produced from the sequencing runs were processed,
and sequences were demultiplexed with CASAVA version 1.8.
The reverse complement of each read was aligned to the custom
shRNA libraries using Bowtie (version 0.12.8). Candidates were
ranked using Fisher’s combined P-value and edgeR. The Fisher’s
combined test allowed P-values across independent data sets to
be combined, bearing on the same overall hypothesis (Fisher
1925).
Immunofluorescence and high-content analysis
Cells were fixed in 4% formaldehyde for at least 30 min, washed
with PBS, and permeabilized with 0.2% Triton X-100 for 5 min.
After 30 min in blocking solution (BS; 0.5% BSA, 0.2% fish
skin gelatin in PBS), cells were incubated with the primary anti-
body diluted in BS for 1 h at room temperature. Cellswerewashed
three times with PBS and incubated with Alexa fluor-labeled sec-
ondary antibodies for 30 min at room temperature. After three
washes with PBS, nuclei were stained with 1 µg/mL DAPI for
10min. The antibodies used are described in Supplemental Table
S2. The high-content analysis is described in detail in the Supple-
mental Material.
BrdU incorporation, SA-β-Gal, and crystal violet staining
BrdU incorporation, SA-β-Gal, and crystal violet staining assays
are described in the Supplemental Material.
mRNA expression analysis
Total RNA was extracted using Trizol reagent (Invitrogen)
per the manufacturer’s instructions. cDNA was generated using
random hexamers and SuperScript II reverse transcriptase
(Invitrogen). Quantitative real-time PCR was performed using
SYBR Green PCR master mix (Applied Biosystems) in a
CFX96 real-time PCR detection system (Bio-Rad). Primers are
listed in Supplemental Table S3. GAPDH expression was used
for normalization.
Preparation of libraries for scRNA-seq and scRNA-seq data analysis
Detailed protocols describing the preparation of Smart-Seq2 and
ICELL8 single-cell libraries as well as scRNA-seq data analysis
are in the Supplemental Material.
Reprogramming experiments with TNG MKOS MEFs
TNG MKOS MEFs were obtained via morula aggregation as de-
scribed previously (Chantzoura et al. 2015). A detailed descrip-
tion of the reprogramming protocol is in the Supplemental
Material.
CM
To produce CM, MEFs were infected with RAS and pooled
shRNAs againstMtor or control vectors and cultured in selection
medium for 11 d, after which the medium was changed to MEF
medium with 0.5% FBS for conditioning. CM was collected and
filtered (0.22 µm) after 3 d in two consecutive rounds. CM ali-
quots were stored at −20°C. For the reprogramming assays, CM
was mixed with 4× concentrated reprogramming medium in a
proportion of 3 to 1.
Coculture experiments
Approximately 2 × 105 MEFs infected with RAS-expressing or
vector control retroviruses were seeded per gelatinized six-well
plate. The next day, 2 × 103 TNG MKOS MEFs were seeded
on top.
Statistical analysis
Statistical analysis of data was conducted using Graphpad Prism
7 software. Unpaired Student’s t-test was used to calculate P-
values.
Accession numbers
RNA-seq data sets have been deposited at the Gene Expression
Omnibus (accession no. GSE95021).
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